Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

MetricMRNAModernaBIIBBiogenINCYIncyte
Snapshot
Price$59.34$199.71$103.66
Market cap$25.38B$29.02B$19.62B
Valuation
P/E—21.1x13.7x
Forward P/E—23x9.8x
Growth
Revenue growth-30.0%1.2%21.5%
EPS growth—-8.1%2455.3%
Profitability
Net margin-143.6%13.8%26.7%
ROE-36.7%7.5%29.2%
Balance sheet & cash
Debt / equity0.07x0.34x0.01x
Free cash flow yield-13.6%6.8%2.2%
Dividend yield———
Verdict
Investment ratingWeak· 17Neutral· 49Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearMRNAtoday $59BIIBtoday $200INCYtoday $104
2027$45.40 – $66.59+12% CAGR$152.78 – $224.07+12% CAGR$1,986.63 – $2,913.72+2711% CAGR
2028$46.31 – $67.92+7% CAGR$155.83 – $228.56+7% CAGR$50,764.45 – $74,454.52+2580% CAGR
2029$47.23 – $69.28+5% CAGR$158.95 – $233.13+5% CAGR$1,297,188.98 – $1,902,543.84+2538% CAGR
2030$48.18 – $70.66+4% CAGR$162.13 – $237.79+4% CAGR$33,147,199.80 – $48,615,893.04+2517% CAGR
2031$49.14 – $72.07+4% CAGR$165.37 – $242.55+4% CAGR$847,013,711.15 – $1,242,286,776.35+2504% CAGR
5-yr CAGR-3.7% – 4.0%-3.7% – 4.0%2312.4% – 2504.5%